5 Aug 2022 , 03:47 PM
Net profit of ERIS Lifesciences declined 11.33% to Rs 94.58 crore in the quarter ended June 2022 as against Rs 106.66 crore during the previous quarter ended June 2021. Sales rose 14.08% to Rs 392.05 crore in the quarter ended June 2022 as against Rs 343.66 crore during the previous quarter ended June 2021.
| Particulars | Quarter Ended | ||
| ? | Jun. 2022 | Jun. 2021 | % Var. |
| Sales | 392.05 | 343.66 | 14 |
| OPM % | 32.95 | 36.81 | – |
| PBDT | 124.71 | 131.60 | -5 |
| PBT | 101.27 | 117.10 | -14 |
| NP | 94.58 | 106.66 | -11 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
